US Patent Issued to Legend Biotech Ireland, Legend Biotech USA on Oct. 20 for "Antibodies and chimeric antigen receptors targeting glypican-3 (GPC3) and methods of use thereof" (Chinese, Canadian Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,766,192, issued on Oct. 20, was assigned to Legend Biotech Ireland Ltd. (Dublin) and Legend Biotech USA Inc..

"Antibodies and chimeric antigen receptors targeting glypican-3 (GPC3) and methods of use thereof" was invented by Xiaohu Fan (Edmonton, Canada), Jie Mao (Nanjing, China), Qiuchuan Zhuang (Nanjing, China) and Ruixue Wang (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are anti-glypican-3 (GPC3) antibodies or antigen binding fragments thereof, and a chimeric antigen receptor (CAR) that binds glypican-3 (GPC3) containing an anti-GPC3 antibody in an extracellular domain, a transmembrane domain, and an intracellular signaling...